Hipertensión portal idiopática secundaria a tratamiento tiopurínico en pacientes con enfermedad inflamatoria intestinal

Suárez Ferrer, Cristina; Llop Herrera, Elba; Calvo Moya, Marta; Vera Mendoza, María Isabel; González Partida, Irene; González Lama, Yago; Matallana Royo, Virginia; Calleja Panero, José Luis; Abreu García, Luis.
Rev. esp. enferm. dig ; 108(2): 79-83, feb. 2016. tab
Artículo en Español | IBECS (España) | ID: ibc-148363

Documentos relacionados

  1. Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease.
  2. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry.
  3. Rac1/pSTAT3 expression: A pharmacodynamic marker panel as a first step toward optimization of thiopurine therapy in inflammatory bowel disease patients.
  4. Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
  5. Improved HPLC Quantification of 6-Mercaptopurine Metabolites in Red Blood Cells: Monitoring Data and Literature Analysis.
  6. Are changes in the blood count clinically useful marker of azathioprine dose?
  7. The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.
  8. Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease.
  9. Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy.
  10. Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases.